A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.
OBJECTIVE
The Alzheimer's Disease Cooperative Study (ADCS) is conducting a clinical trial to address whether chronic valproate treatment can delay emergence of behavioral symptoms in outpatients with AD. Since there were no data on the safety and tolerability of divalproex sodium in outpatients with dementia, we undertook a pilot study to inform the design of the ADCS study.


METHODS
We recruited 20 outpatients with probable AD, MMSE 10-20, without history of agitation or psychosis. This was a 10-week randomized, double-blind, placebo-controlled study assessing the safety and tolerability of 1,000 mg/day and 1,500 mg/day of divalproex sodium delayed-release for 8 weeks followed by extended-release for 2 weeks. Other outcome measures addressed cognition, function, global status, side effects, and laboratory data.


RESULTS
Participants assigned to active treatment ingested approximately 30% less of their prescribed study medication compared to those receiving placebo (p < .05 Wilcoxon Rank Sum test). The average tolerated dose for all participants at week 8 was 810 mg/day or 11.5 mg/kg/day, similar to the dose tolerated by nursing home patients. The most common side effects were sleepiness and tiredness, with worse cognitive performance in those assigned to 1500 mg/day.


CONCLUSIONS
These results were used to design the multi-center ADCS trial. Doses of less than 1000 mg/day of divalproex sodium were the maximum tolerated by these outpatients with AD. A larger study of divalproex sodium dose tolerability is needed to define treatment in outpatients with Alzheimer's disease.
Profenno
Louis A
LA
Department of Psychiatry, University of Rochester Medical Center, NY 14620, USA.
Jakimovich
Laura
L
Holt
Connie J
CJ
Porsteinsson
Anton
A
Tariot
Pierre N
PN
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects*; D004311:Double-Blind Method; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects; D010045:Outpatients; D010865:Pilot Projects; D010919:Placebos; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage* / Q000009:adverse effects*
D000927:Anticonvulsants; D018696:Neuroprotective Agents; D010919:Placebos; D014635:Valproic Acid